NMRA
Neumora Therapeutics, Inc.
0.55$
-7.7%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | |
| – | – | – | +73.9% | -75.2% | – | – | |
| – | – | – | – | – | – | – | |
| – | – | +144.2% | -50.8% | +36.2% | +40.8% | -12.4% | |
| – | – | +192.5% | +26.8% | +46.1% | +37.5% | -3.9% | |
| – | – | +148.5% | -42.7% | +38.0% | +40.5% | -10.4% | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | -1,613.1% | – | -33.6% | -27.0% | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.